The investigational antibody promotes the activation of both natural killer cells and T cells, with the potential to elicit a strong anti-tumor response and promote immunological memory, according to a statement.
Surface Oncology will receive a $30 million milestone payment at the start of the first phase 1 study for GSK4381562. The company is also eligible to receive an additional $700 million in future milestone payments, as well as tiered royalties on global net sales.
Price: 5.89, Change: +0.12, Percent Change: +0.02
|Stifel Adjusts Zendesk's Price Target to $85 From $1...|
|Holley to Join Russell 2000 Index|
|US Futures Extend Gains on Easing Inflation Expectat...|
|Street Color: Treasuries Under Modest Pressure With ...|
|Charge Enterprises to Be Added to Russell Indexes|